4-(dibenzo[b,e]thiepin-11(6H)-ylidene)-1-piperidinebutyric acid | 219595-14-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫平类
• 英文名称: 4-(dibenzo[b,e]thiepin-11(6H)-ylidene)-1-piperidinebutyric acid
• 英文别名: 4-[4-(6H-benzo[c][1]benzothiepin-11-ylidene)piperidin-1-yl]butanoic acid
• CAS: 219595-14-9
• 化学式: C₂₃H₂₅NO₂S
• 分子量: 379.523
• InChiKey: SRCUUFSHOKSNML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  65.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Piperidine compounds, method for preparation thereof, and a pharamceutical composition comprising the same
  申请人：HOKURIKU PHARMACEUTICAL CO., LTD.

  公开号：EP0451772A1

  公开（公告）日：1991-10-16

  Novel piperidine compounds represented by the following formula (I): wherein Y represents an alkylene group having 1 to 7 carbon atoms; A is a group represented by formula I-a or formula I-b: wherein X represents -CH₂-S- or -S-; and R represents a hydrogen atom or a lower alkyl group with a proviso that A is a group represented by formula I-a, or R represents a hydrogen atom with a proviso that A is a group represented by formula I-b and pharmacologically acceptable salts thereof are disclosed. Also disclosed are a method for preparing the same; a pharmaceutical composition comprising the same; an antiallergic agent and an agent for bronchial asthma comprising the same; and a method for treatment of an allergic disease or bronchial asthma comprising the step of administering the same.

  本发明公开了以下式子（I）所表示的新型哌啶化合物：其中，Y代表具有1至7个碳原子的烷基；A是由式子I-a或式子I-b表示的基团：其中，X代表-CH₂-S-或-S-；R代表氢原子或较低的烷基，但在A是由式子I-a表示的基团时，R代表氢原子；在A是由式子I-b表示的基团时，R代表氢原子，其药理学上可接受的盐也被揭示。本发明还公开了一种制备该化合物的方法；包含该化合物的制药组合物；包含该化合物的抗过敏剂和支气管哮喘剂；以及通过给予该化合物进行治疗过敏性疾病或支气管哮喘的方法。
• Novel heterocyclic compounds
  申请人：——

  公开号：US20020151539A1

  公开（公告）日：2002-10-17

  The present invention relates to novel N-substituted azaheterocyclic compounds of the general formula 1 wherein X, Y, Z, R 1 , R 2 and m are as defined in the detailed part of the present description, or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation, as well as their use for treatment of indications caused by or related to the secretion and circulation of insulin antagonising peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.

  本发明涉及通式如下的新型 N-取代杂杂环化合物 1 其中 X、Y、Z、R 1 , R 2 或其盐，以及它们的制备方法、含有它们的组合物和它们在临床治疗疼痛、痛觉减退和/或炎症（其中 C 纤维通过引起神经源性疼痛或炎症发挥病理生理作用）方面的用途，以及它们在治疗由胰岛素拮抗肽的分泌和循环引起或与之相关的适应症（如非胰岛素依赖型糖尿病（NIDDM）和老年性肥胖）方面的用途。例如，非胰岛素依赖型糖尿病（NIDDM）和与衰老相关的肥胖症。
• NOVEL HETEROCYCLIC COMPOUNDS
  申请人：NOVO NORDISK A/S

  公开号：EP0991633A1

  公开（公告）日：2000-04-12
• US6391890B1
  申请人：——

  公开号：US6391890B1

  公开（公告）日：2002-05-21
• [EN] NOVEL HETEROCYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES HETEROCYCLIQUES
  申请人：NOVO NORDISK A/S

  公开号：WO1999000376A1

  公开（公告）日：1999-01-07

  (EN) The present invention relates to novel N-substituted azaheterocyclic compounds of general formula (I), wherein X, Y, Z, R1, R2 and m are as defined in the detailed part of the present description, or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation, as well as their use for treatment of indications caused by or related to the secretion and circulation of insulin antagonising peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.(FR) L'invention porte: sur de nouveaux composés azahétérocycliques substitués en N de formule générale (I) dans laquelle X, Y, Z, R1, R2 et m sont définis en détail dans la description, ou leurs sels; sur leurs procédés de préparation, sur des compositions les contenant, et sur leur utilisation pour le traitement clinique de troubles douloureux hyperalgésiques et/ou inflammatoires où les fibres C jouent un rôle pathophysiologique générateur des douleurs ou d'inflammation; ainsi que sur le traitement de cas dus ou liés à la sécrétion et à la circulation de peptides antagonistes de l'insuline tels que le diabète sucré non insulino-dépendant, et l'obésité liée à l'âge.